Xconomy -- San Diego’s Ambit Biosciences, which is developing anti-cancer therapies by developing a wide array of small molecule drug compounds to block certain kinase-based reactions, has raised $15 million of a planned $15.9 million round of debt, rights and securities, according to a recent regulatory filing. The company, previously known as Aventa Biosciences, raised $49.3 million Series D round in 2007, according to VentureWire. Investors include Avalon Ventures, Forward Ventures, Genechem, GIMV, Horizon Technology Finance, Jov-CMDF, MedImmune Ventures, NovaQuest, OrbiMed Advisors, Perseus-Soros Biopharmaceutical Fund, Radius Ventures, and Roche Venture Fund.
